FIVE PRIME THERAPEUTICS INC License Agreements
12 Contracts & Agreements
- Amendment No. 4 to the Non-Exclusive License Agreement by and among the company, BioWa, Inc. and Lonza Sales AG, dated as of August 22, 2019 (Filed With SEC on November 6, 2019)
- Amendment No. 3 to the Non-Exclusive License Agreement by and among the company, BioWa, Inc. and Lonza Sales AG, dated as of July 17, 2019 (Filed With SEC on November 6, 2019)
- Amendment No. 2 to the Non-Exclusive License Agreement by and among the company, BioWa, Inc. and Lonza Sales AG, dated as of April 27, 2018 (Filed With SEC on February 26, 2019)
- Amendment No. 1 to the Non-Exclusive License Agreement by and among the company, BioWa, Inc. and Lonza Sales AG, dated as of June 6, 2013 (Filed With SEC on February 26, 2019)
- Amendment No. 2 to the Exclusive License Agreement by and between the company and Galaxy Biotech, LLC, dated as of May 30, 2017 (Filed With SEC on February 27, 2018)
- Amendment to the Exclusive License Agreement (Filed With SEC on August 5, 2016)
- AMENDMENT NO. 1 TO THE LICENSE AGREEMENT EFFECTIVE FEBRUARY 1, 2006 BETWEEN STANFORD UNIVERSITY AND FIVE PRIME THERAPEUTICS INC. (Filed With SEC on August 23, 2013)
- NON-EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on August 16, 2013)
- EXCLUSIVE LICENSE AGREEMENT between THEREGENTS OF THE UNIVERSITY OF CALIFORNIA and FIVE PRIME THERAPEUTICS, INC. for RECEPTORS FOR FIBROBLAST GROWTH FACTORS UC Case No. *** TABLE... (Filed With SEC on August 16, 2013)
- Exclusive License Agreement (Filed With SEC on August 16, 2013)
- EXCLUSIVE LICENSE AGREEMENT between THEREGENTS OF THE UNIVERSITY OF CALIFORNIA and FIVE PRIME THERAPEUTICS, INC. for RECEPTORS FOR FIBROBLAST GROWTH FACTORS UC Case No. *** TABLE... (Filed With SEC on July 26, 2013)
- Exclusive License Agreement (Filed With SEC on July 26, 2013)
